Chemistry: molecular biology and microbiology – Measuring or testing process involving enzymes or... – Involving antigen-antibody binding – specific binding protein...
Reexamination Certificate
2005-11-21
2009-10-06
Yu, Misook (Department: 1642)
Chemistry: molecular biology and microbiology
Measuring or testing process involving enzymes or...
Involving antigen-antibody binding, specific binding protein...
C435S007230
Reexamination Certificate
active
07598043
ABSTRACT:
The present invention is directed to a method of inhibiting tumor formation in a cancer patient at a site remote from sites of prior tumor formation and to a method of preventing metastases. These methods involve administering to the cancer patient an inhibitor of vascular endothelial growth factor receptor 1+bone marrow-derived cells under conditions effective either to inhibit tumor formation in the cancer patient at a site remote from sites of prior tumor formation or to prevent metastases. Candidate compounds useful for such purposes can be screened depending on whether they bind to vascular endothelial growth factor receptor 1+bone marrow-derived cells. Metastases in a cancer patient can be monitored by evaluating a patient sample for detection and quantification of vascular endothelial growth factor receptor 1+bone marrow-derived cells and comparing the level of vascular endothelial growth factor receptor 1+bone marrow-derived cells to prior levels.
REFERENCES:
patent: 6617160 (2003-09-01), Shitara et al.
patent: 6811779 (2004-11-01), Rockwell et al.
patent: WO 03/014326 (2003-02-01), None
patent: WO 03/019136 (2003-03-01), None
Hattori et al, Nature Medicine, 2002, 8:841-849).
Chen et al., Cancer Lett, Sep. 2004, 213:73-82.
Lyden et al., “Impaired Recruitment of Bone-Marrow-Derived Endothelial and Hematopoietic Precursor Cells Blocks Tumor Angiogenesis and Growth,”Nat. Med.7(11):1194-1201 (2001).
Hiratsuka et al., “MMP9 Induction by Vascular Endothelial Growth Factor Receptor-1 Is Involved in Lung-Specific Metastasis,” Cancer Cell 2:289-300 (2002).
Kaplan Rosandra N.
Lyden David
Rafii Shahin
Riba Rebecca D.
Cornell Research Foundation Inc.
Halvorson Mark
Nixon & Peabody LLP
Yu Misook
LandOfFree
Use of vascular endothelial growth factor receptor 1+ cells... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Use of vascular endothelial growth factor receptor 1+ cells..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of vascular endothelial growth factor receptor 1+ cells... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4128499